|
Understanding and Treatment of Childhood Onset Dermatomyositis Clinical Trials Resources presented on Clinical Trials Search isn't meant to be a substitute for qualified health advice, visits or professional assistance with a real medical. We aren't doctors. Always consult your mD about Understanding and Treatment of Childhood Onset Dermatomyositis conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Understanding and Treatment of Childhood Onset Dermatomyositis Clinical research trials and Understanding and Treatment of Childhood Onset Dermatomyositis health trials occur in a lot of of places throughout the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectivity of new does drugs. The role of the studies / projects is to resolve certain human healthcare questions. Clinical trials are a popular way for doctors, government agencies, and private sector corporations to detect remedies for all varieties of circumstances, such as Understanding and Treatment of Childhood Onset Dermatomyositis. Understanding and Treatment of Childhood Onset Dermatomyositis Clinical Trials and other clinical trials allow volunteers to obtain health treatment choices before they are available to the general public. Most times the human subjects recieve professional assistance for free of charge, and every now and again they are paid for their time. Sometimes there is a cost for a Understanding and Treatment of Childhood Onset Dermatomyositis clinical trial. Human subjects frequently get the finest healthcare available for their Understanding and Treatment of Childhood Onset Dermatomyositis condition. Risks are a reality, however, and may include extra or frequent physician visits, medical dangers (possibly life-threatening), and/or the treatment being uneffective. Trials are federally governed with strict guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "U" Clinical Trials Conditions > Understanding and Treatment of Childhood Onset Dermatomyositis  Understanding and Treatment of Childhood Onset Dermatomyositis
Understanding and Treatment of Childhood Onset Dermatomyositis
For Condition: Dermatomyositis
Status: Not yet recruiting
Sponsor(s): National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) , Immunex Corporation
Synopsis: Juvenile dermatomyositis (JDMS) is one of the most serious of the childhood rheumatic diseases. The theory behind this trial is that early introduction of etanercept or methotrexate will prove to be effective in the treatment of JDMS. Pretreatment muscle biopsies, we believe there will be abnormalities in the blood vessels that will be correlated with worse physical strength and daily functional ability. The long-term goal is to improve the treatment of this serious childhood onset rheumatic disease and to better understand the pathogenic mechanism for the development of the vasculopathy (disorder of blood vessels) of JDMS. Identification of the specific mechanism of the vasculopathy may allow for the rational introduction of biologic treatments focused on vascular growth.
Details: The mortality of JDMS is 3-39% with over 40% of patients demonstrating long-term disability. Current first line therapy is high-dose corticosteroids with the attendant significant drug-related toxicity. Over 30% of JDMS patients fail to respond adequately to steroids and require additional immunosuppression, none of which have been tested in prospective, randomized, controlled trials. The unique occlusive vasculopathy in JDMS is critical in the pathogenesis and predictive of prognosis but poorly understood. Elevated levels of tumor necrosis factor (TNF) alpha have been shown to be present in JDMS and are associated with a more severe and chronic course. Seventy-five children with definite JDMS will be enrolled in a 24-month prospective, randomized, multicentered trial comparing 3 treatments: oral prednisone (P), combination of oral prednisone and methotrexate (P/MTX), and combination of oral prednisone and etanercept (P/E). Primary response measures will be muscle strength and mean duration of steroid therapy. Secondary response variables are disability in daily function and height and weight growth velocity (steroid toxicity measures). The combination of P/E will be tested and compared to both P alone and the combination of P/MTX after 3, 6, 12, 18, and 24 months of treatment. In addition, the combination of P/MTX will be compared to P alone after 3, 6, 12, 18, and 24 months of treatment. In pretreatment muscle biopsies, proangiogenic factors (such as vascular endothelial cell growth factor and basic fibroblast growth factor), angiostatic factors (such as angiostatin and endostatin), and vascular morphology (vessel number, width, length and area) will be quantified and tested for ability to predict muscle strength and functional ability 3, 6, 12, 18, and 24 months later.
Eligibility:
Study Type: Interventional, Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 4 Years/16 Years
Genders: Both
Protocol Entry Criteria: Inclusion criteria at the time of enrollment: - Definite or probable diagnosis of JDMS by the criteria of Bohan and Peter - No prior systemic steroid treatment for JDMS - If able to become pregnant (females) or impregnate (males) and are sexually active, then must have negative serum pregnancy test at baseline and be utilizing effective form of birth control - Patient and/or parent or legal guardian must be willing to sign consent and assent forms Exclusion criteria at the time of enrollment: - History of chronic or recurrent infections sufficient to preclude the use of etanercept - Prior treatment with specific TNF-blocking agents - Demonstration of cutaneous or gastrointestinal (GI) ulceration at the time of diagnosis - JDMS-related pulmonary disease at time of diagnosis (interstitial lung disease or aspiration pneumonia confirmed by radiograph) - JDMS-related cardiomyopathy (echocardiogram confirmation) - Any uncontrolled, clinically significant pre-existent systemic disease (hepatic, renal, neurological, endocrine, cardiac, gastrointestinal, or hematologic disease) within 24 weeks of start of study - Known HIV, hepatitis B surface antigen not related to vaccination, or hepatitis C antibody positivity - Pregnant or nursing female - Any of the following laboratory abnormalities at baseline: platelet count < 100,000/cmm, total white cell count of < 3000 cells/cmm, neutrophils < 1000 cells/cmm, serum bilirubin > 2 times upper limit of normal, estimated creatinine clearance of < 90 mL/min/1.73 M2 BSA estimated by formula for males age 2 to <13 (0.55 X ht in cms/serum creatinine), age 13-18 (0.7 X ht in cms/serum creatinine) and females age 2-18 (0.55 X ht in cms/serum creatinine) - Received live virus vaccination within 3 months prior to study entry (contraindication for MTX or etanercept therapy) - Past or current substance abuse or psychiatric history that would interfere with ability to give informed consent or comply with study requirements or physician instructions
Total Enrollment: 75
Location and Contact Information:
Overall Study Official:
DanielLovell, Principal Investigator, Cincinnati Children's Hospital Medical Center
Cincinnati Childrens Hospital Medical Center
Cincinnati, Ohio, 45229
United States
Daniel Lovell 513-636-8071
Additional Information:
Study ID Numbers: NIAMS-078; P60 AR47784
Study Start Date:
Record last reviewed: March 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00035958
Other Dermatomyositis Studies:
1. Myositis in Children
2. Safety and Effectiveness of h5G1.1-mAb for Dermatomyositis
3. Intravenousimmunoglobulin (IVIg) for the Treatment of Inflammatory Myopathies
4. Methimazole to Treat Polymyositis and Dermatomyositis
5. Understanding and Treatment of Childhood Onset Dermatomyositis
Related Studies:
Other Dermatomyositis Clinical Trials
Other Ohio Clinical Trials
Other Cincinnati Clinical Trials
Understanding and Treatment of Childhood Onset Dermatomyositis
|
|
|
|
|
|
|
|
